THE EFFECT OF RECOMBINANT INTERLEUKIN-2 IN COMBINATION WITH MITOMYCIN-C ON ADVANCED CANCER

被引：3

作者：

AKIYOSHI, T

ARINAGA, S

NANBARA, S

KARIMINE, N

INOUE, H

TAKAMUKU, K

ABE, R

WATANABE, D

NAGAMATSU, M

MATSUOKA, H

UEO, H

机构：

[1] The Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 69, Beppu

来源：

JAPANESE JOURNAL OF SURGERY | 1990年 / 20卷 / 03期

关键词：

advanced cancer; mitomycin C; recombinant interleukin 2;

D O I：

10.1007/BF02470676

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

We recently discovered that the ability of cancer patients to generate lymphokine-activated killer (LAK) cells became remarkably augmented after mitomycin C (MMC) administration. Based on our clinical findings, we designed a treatment regimen comprised of MMC 12 mg/m2 given intravenously on day 1 and recombinant interleukin 2 (rIL 2) 700 U/m2 given intravenously every 12 hr from day 4 through day 8, when the generation of LAK cells had been shown to be markedly increased. Ten patients with various advanced carcinomas for which standard therapy had failed or no standard therapy was available, were treated with this regimen. Of these ten, three had a partial response and three others had a minor response. Fevers were common and anemia occurred in four patients, but nevertheless, severe toxicity was not encountered. These results indicated that rIL 2 in combination with MMC might be effective against advanced carcinoma without causing severe toxicity when these drugs are used in an appropriate combination. © 1990 The Japan Surgical Society.

引用

页码：365 / 368

页数：4

共 12 条

[1]

Ogura T., Shindo H., Shinzato O., Namba M., Masuno T., Inoue K., Kishimoto S., Yamamura Y., In vitro tumor killing by peritoneal macrophages from mitomycin C treated rats, Cancer Immunol Immunother, 13, pp. 112-117, (1982)

[2]

Shindo H., Ogura T., Masuno T., Hayashi S., Kishimoto S., Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice, Cancer Immunol Immunother, 20, pp. 145-150, (1985)

[3]

Akiyoshi T., Arinaga S., Tsuji H., Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C, Cancer Immunol Immunother, 24, pp. 259-262, (1987)

[4]

Arinaga S., Akiyoshi T., Tsuji H., Augmentation of the generation of OK-432 activated killer cells after a single dose of mitomycin C in cancer patients, Int J Immunopharmacol, 10, pp. 47-51, (1988)

[5]

Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., Matory Y.L., Skibber J.M., Shiloni E., Vetto J.T., Seipp C.A., Simpson C., Reichert C.M., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, pp. 1485-1492, (1985)

[6]

Rosenberg S.A., Lotze M., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp C.A., Simpson C.G., White D.E., A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N Engl J Med, 316, pp. 889-897, (1987)

[7]

West W.H., Tauer K.W., Yannelli J.R., Marshall G.D., Orr D.W., Thurman G.B., Oldham R.K., Constant-infusion recombinant interleukin-2 in adoptive immuno-therapy of advanced cancer, N Engl J Med, 316, pp. 898-905, (1987)

[8]

Lotze M.T., Chang A.E., Seipp C.A., Simpson C., Vetto J.T., Rosenberg S.A., High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer: response, treatment-related morbidity, and histologic findings, JAMA, 256, pp. 3117-3124, (1986)

[9]

Hinuma S., Onda H., Naruo K., Ichimori Y., Koyama M., Tsukamoto K., Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes, Biochem Biophys Res Commun, 109, pp. 363-369, (1982)

[10]

Lotze M.T., Matory Y.L., Ettinghausen S.E., Rayner A.A., Sharrow S.O., Seipp C.A., Custer M.C., Rosenberg S.A., In vivo administration of purified human interleukin 2: II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2, J Immunol, 135, pp. 2865-2874, (1985)

← 1 2 →